Gapping up
In reaction to strong earnings/guidance:
- ZUO +20.5%, LX +11.2%, SCWX +7%, GWRE +6.1%, GEF +3.1%, TLYS +3%, NAV +2.5%, GIII +0.5%
Other news:
- KZR +44.3% (announces updated results from Phase 1b portion of MISSION study)
- IBIO +21.2% (initiated preclinical immunization studies for its second COVID-19 vaccine platform)
- ATSG +13.4% (AMZN expands aircraft fleet with the leasing of 12 Boeing 767-300 aircraft from ATSG)
- RM +6.3% (provides business update)
- WWW +6.3% (provides update on Q2 trends)
- NIO +6.1% (reports May deliveries of 3,436 vehicles, representing a strong 215.5% growth year over year)
- AVXL +6% (received a No Objection Letter from Health Canada as well as Clinical Trial Authorization from the Medicines and Healthcare products Regulatory Agency in the United Kingdom to expand the Phase 2b/3 safety and efficacy trial of ANAVEX)
- FNKO +4.9% (expects to reduce its global workforce by approximately 25%)
- AAL +4.4% (increases domestic flying for summer travel season)
- INO +3.8% (files complaint seeking to compel VGXI)
- BA +3.4% (AMZN expands aircraft fleet with the leasing of 12 Boeing 767-300 aircraft from ATSG)
- FIT +3% (introduces low-cost emergency ventilator offering Fitbit Flow)
- GLUU +2% (prices offering of 15,000,000 shares of common stock at $9.25 per share)
- ESPR +1.9% (announces NEXLIZET is now available in U.S. pharmacies)
- COST +1.1% (reports May comps)
- SABR +1% (takes steps for strategic realignment of its airline and agency-focused businesses, as well as other measures to support the new organizational structure)
Analyst comments:
- SEAS +3.3% (upgraded to Buy from Neutral at Citigroup)
- TSN +2.3% (upgraded to Outperform from Mkt Perform at Bernstein)
- SYKE +1.5% (upgraded to Outperform from Neutral at Robert W. Baird)
- VVV +1% (upgraded to Buy from Hold at SunTrust)
- CMA +0.9% ( upgraded to Buy from Neutral at B. Riley FBR)
- MEOH +0.8% (upgraded to Sector Outperform from Sector Perform at Scotiabank)